Frailty is a syndrome characterized by the gradual decline in physical function, strength, and endurance, typically associated with aging. Frailty increases the risk of falls, fractures, disability, and death, making early detection and intervention critical. The onset of frailty is often subtle and difficult to identify in its early stages, which is why there is increasing interest in finding reliable biomarkers for its detection.
Sclerostin has emerged as a potential biomarker for the early detection of frailty due to its involvement in both bone metabolism and muscle function. Studies suggest that changes in sclerostin levels are associated with age-related declines in skeletal muscle mass, strength, and function — all of which are central components of frailty.
Biomedica’s Sclerostin ELISA Kit was used in a first time study that explored the association between circulating sclerostin levels and frailty. Click below for the full publication, where you can find the abstract and key findings!
If you have any questions about this kit or any of our other offerings, contact us here.